High-throughput screening in niche-based assay identifies compounds to target preleukemic stem cells

Current chemotherapies for T cell acute lymphoblastic leukemia (T-ALL) efficiently reduce tumor mass. Nonetheless, disease relapse attributed to survival of preleukemic stem cells (pre-LSCs) is associated with poor prognosis. Herein, we provide direct evidence that pre-LSCs are much less chemosensit...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Invest
Autores principales: Gerby, Bastien, Veiga, Diogo F.T., Krosl, Jana, Nourreddine, Sami, Ouellette, Julianne, Haman, André, Lavoie, Geneviève, Fares, Iman, Tremblay, Mathieu, Litalien, Véronique, Ottoni, Elizabeth, Kosic, Milena, Geoffrion, Dominique, Ryan, Joël, Maddox, Paul S., Chagraoui, Jalila, Marinier, Anne, Hébert, Josée, Sauvageau, Guy, Kwok, Benjamin H., Roux, Philippe P., Hoang, Trang
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Clinical Investigation 2016
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5127686/
https://ncbi.nlm.nih.gov/pubmed/27797342
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI86489
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares